Recursos Técnicos - Notas de Aplicación
A Semi-Automated, Non-Radioactive Assay for the Detection of Antibody-Based Complement-Dependent CytotoxicityDescargar
March 26, 2012
This application note describes the use of a nonradioactive, bioluminescent antibody-based complement-dependent cytotoxicity (CDC) assay. The simple protocol details the sequential addition of cells, antibody therapeutic, complement, and reagents that can be readily automated with a simple, inexpensive pipetting station. This application note demonstrates the semi-automation of the CDC assay using Daudi cells, rituximab (monoclonal antibody used in the drug Rituxan), and baby rabbit complement.
Pharmaceutical companies are increasingly focused on biologic therapeutics rather than biochemical, chemical, and radiological compounds for many cancer treatments. Biologic therapeutics only target and destroy specific cancer cells, thus preventing damage to surrounding, healthy cells and reducing unwanted cytotoxic events. The most prominent and successful example is Rituximab (Rituxan; Roche/Genentech), a chimeric monoclonal antibody (mAb) therapy that is used for certain cancers and autoimmune disorders.
In spite of increased biologics research, specific mAb antitumor mechanisms remain undefined. Evidence is mounting to suggest that antibody dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) both play a role in tumor cell lysis, but the importance of each, and any synergistic or antagonistic interrelation is as of yet unclear.¹ ADCC is a prominent mechanism in the host immune defense where antibodies bind to a target cell and subsequently recruit effector cells, such as natural killer (NK) cells, to bind via Fc receptors. The NK cells then engulf and destroy the target cell. On the other hand, in the CDC mechanism, antibodies once again bind to a target cell through a specific antigen, but activate the complement cascade, a multipathway attack on the target cell (Figure 1), rather than recruiting NK cells.
Figure 1. Principle of CDC specific to Rituxan.
As each mechanism may play a role in anti-tumor mechanisms, biologics research should not solely focus on ADCC assays, but should also include CDC assays to obtain a true mechanistic profile. Presented here is a nonradioactive, bioluminescent antibody-based CDC assay (Figure 2) that quantitatively measures release of glyceraldehyde3-phosphate dehydrogenase (GAPDH) naturally found in primary, mammalian and bacterial cells. In this manner, prelabeling, transfection, transformation, and other methods to artificially introduce molecules into cells is negated. The reagents may be used for CDC and ADCC assays.
Adding automation to the assay process can reduce variability compared to manual methods. Additionally, automated instruments can increase throughput and decrease overall project time.
Figure 2. aCella-TOX CDC-based assay principle based on the release of endogenous glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The assay kit contains the enzyme 3-phosphoglyceric phosphokinase (PGK) to produce ATP, which is then used in conjunction with luciferase and luciferin to generate luminescence.
Materials and methods
Daudi cells (human Burkitt’s lymphoma cell line, part number CCL-213) were obtained from ATCC (Manassas, VA) and used as target cells in the CDC assay. Rituximab, the monoclonal antibody in the drug Rituxan, and aCella-TOX (part number CLATOX 100-3) were provided by Cell Technology, Inc (Mountain View, CA). Baby rabbit complement (part number CL3441-S) was purchased from Cedarlane Laboratories (Burlington, NC).
Daudi Cell Propagation Medium consisted of RPMI 1640 (part number 11875), Heat Inactivated Fetal Bovine Serum, 10% (part number 10082), NEAA, 1X (part number 11140), and Pen-Strep-Glutamine, 1X (part number 10378). The aforementioned reagents were supplied by Life Technologies Corporation (Grand Island, NY).
Clear, round-bottom TC-treated 96-well microplates (part number 3799) were used for antibody dilution and to perform the cell lysis portion of the assay procedure. 96-well white, flat bottom, PS, nontreated microplates (part number 3912) were then used for lysate transfer, aCella-TOX reagent addition, and luminescent signal detection. Both plate types were provided by Corning Life Sciences (Corning, NY).
The Agilent BioTek Precision microplate pipetting system combines an eight-channel pipetting head and an eightchannel bulk reagent dispenser in one instrument.
The instrument was used to dispense all assay components, including target (Daudi) cells and complement, serially titrate antibody across a 96-well polypropylene plate, transfer samples from plate to plate, and dispense the aCella-TOX assay components.
The Agilent BioTek Synergy H4 hybrid multimode microplate reader combines filter- and monochromator-based detection systems in the same unit. A dedicated luminescence detection system was used to quantify the luminescent signal from each assay well. The plates were read in kinetic mode, using integrated Agilent BioTek Gen5 data analysis software, to capture the luminescent signal every 5 minutes.
Automated CDC assay procedure
A 20 µL of Daudi target cells, at a concentration of 2 X 105 cells/mL, were added to each well of the 96-well assay plate. A 10-point titration curve of the test antibody was then created using 1:2.5 serial dilutions beginning at 1 µg/mL. Then, 25 µL of each antibody dilution was added to the plate to start the reaction. The plate was shaken for 30 seconds and then placed in a 37 °C/5% CO2 incubator for 15 minutes to allow the cells to opsonize. Baby rabbit complement was then diluted in Daudi cell medium, and 25 µL was added to the appropriate wells. Following shaking for 30 seconds, the plate was incubated at 37 °C/5% CO2 for 30 minutes. The plate was then removed from the 37 °C incubator and allowed to cool to room temperature (RT) for 15 minutes. The target cells in the maximum lysis control wells were then lysed by adding 10 µL of the lysis buffer, and the plate was incubated on the benchtop for an additional 5 minutes at RT. A 125 µL of Daudi cell medium was then added to each well to bring the volume to 200 µL. The plates were centrifuged for one minute at 750 RPM. 50 µL of enzyme assay diluent was then transferred to the appropriate wells of an opaque white luminescence plate. Then, 50 µL of each reaction supernatant was transferred to wells containing the assay diluent. Then, 100 µL of 2X enzyme assay reagent (containing G3P), followed by 50 µL of 1X detection reagent, was added to each diluted supernatant. The plates were again shaken for 30 seconds and immediately read in luminescence mode using the Agilent BioTek Synergy H4 at 5-minute intervals. The percent total cytotoxicity values were graphed and data reduced by four-parameter fits for analysis.Percent total cytotoxicity calculation
The luminescent signal from the wells containing media and other assay components was subtracted from all other wells to correct for background interference. Average nonlysed target cell-only control well signal was then subtracted from all sample wells. Percent total cytotoxicity was then calculated by dividing adjusted sample well signal by the average maximum lysis signal, and multiplying the result by 100.
Results and discussion
Automated versus manual processing comparison
Initial tests were performed to confirm the automated method’s ability to generate results similar to manual processing (Figure 3). All assay steps were performed either robotically, using the Agilent BioTek Precision, or manually using the procedure previously explained. The 5,000 Daudi cells/well as well as a final 1X complement concentration of 5% were used for the test.
Figure 3. Dose response curves and EC50 values generated using the Precision (A) or manually (B).The cytotoxicity curve and EC50 value similarities, when compared to manual data generated by Cell Technology, demonstrate that robotic processing can generate results equivalent to those produced manually. The differences seen in percent total cytotoxicity are explained by the fact that different complement lots, and therefore different background levels, were seen in the assay.
Variable assay parameter analysis
Assay parameter optimization is essential to ensuring appropriate data and the best possible assay window. Two specific parameters that may have a profound effect on data accuracy are the percentage of complement added to the target cells and antibody and the incubation time after all three components are combined. Therefore, it is highly recommended to optimize these conditions before proceeding with antibody testing and validation.
This was accomplished by testing 2.5 to15% complement concentrations (Figure 4), and incubation times of 30, 75, and 120 minutes (Figure 5). EC50 values and signal:background (S:B) ratio were used to determine the most optimal conditions.
Figure 4. Variable complement concentration results. Final 1X concentrations of 2.5, 5, and 15% tested. Assay incubation time equaled 30 minutes.
Figure 5. Variable assay incubation time results. Post complement addition incubation times included 30, 75, and 120 minutes. Final 1X complement concentration equaled 5%.
While the EC50 values were equivalent with each test, maximum percent cytotoxicity and background values varied with each complement concentration tested. Background values were lower using 2.5% complement, however a much lower maximum cytotoxicity was achieved. Equivalent higher values were seen using 5% and 15% complement, although background values increased to a greater extent using the highest percentage. Therefore, a final complement concentration of 5% was shown to yield the largest S:B ratio for the assay.
Variable incubation test results demonstrate that while maximum percent cytotoxicity values are similar with each incubation time, the background increases dramatically and EC50 values are right-shifted with increased incubation. This not only affects the assay window, but can also cause a false decrease in apparent therapeutic potency.
Automated assay robustness validation
Delivering robust, repeatable data is critical to automating an assay procedure. This was tested by performing multiple CDC assay runs using the same complement lot (Figure 6), as well as testing multiple individual complement lots (Figure 7). The previously optimized assay conditions of 5% (1X) complement and a thirty minute post-complement incubation time were incorporated into these tests.
The cytotoxicity curve similarities across the three runs using the same complement lot, as well as EC50 values, demonstrates that the Precision consistently titrates the antibody and dispenses assay components. This is further proven when examining results using separate complement lots. While the actual EC50 values vary slightly, which is explained by variations in the immune response from individual animals, a similar curve shape is seen, and there is little variation between replicates at each antibody concentration.
Figure 6. Results from three independent CDC assay runs using 5,000 Daudi cells/well, and a 5% concentration of one individual complement lot.
Figure 7. Results from a single CDC assay run using 5,000 Daudi cells/well, and a 5% concentration of three individual complement lots.
The optimization and validation results demonstrate that the automated procedure, using an Agilent BioTek Precision microplate pipetting system, can produce an equivalent performance relative to manual processing using identical detection technology. However, the automated process can relieve the operator of tedious tasks, reduce human error associated with repetitive procedures, and provides the operator with time to commit to other more pressing tasks. In addition, the automated procedure can be conducted in laminar flow hoods to help maintain sterile conditions. Finally, the combination of assay chemistry, appropriate microtiter plates, and automation creates a robust process to help ascertain a clearer picture of what antibody-dependent cytotoxic processes are elicited to kill a target cancer cell.
- Wang, S.Y.; Weiner, G. Complement and cellular cyto toxicity in antibody therapy of cancer. Expert Opin Biol Ther. 2008, 8(6), 759-768.